1. Introduction {#sec1}
===============

Alzheimer\'s disease and related dementia (ADRD) is a growing problem in Canada, affecting an estimated 747,000 people in 2012, with 25,000 new cases diagnosed every year \[[@bib1]\]. In British Columbia, cholinesterase inhibitors (ChEIs) are commonly prescribed for treatment of ADRD, where the B.C. Ministry of Health requires a baseline cognitive assessment as part of its Special Authority process \[[@bib2]\]. Because little data exist beyond the 6-month to one-year clinical trials and this group of medications is frequently prescribed to patients with ADRD, there is an opportunity for observational data to assess longer-term safety and effectiveness \[[@bib3]\].

ChEIs increase cholinergic function by preventing the breakdown of acetylcholine, a neurotransmitter that supports communication among nerve cells when its levels are sufficiently high. Acetylcholinesterase is an enzyme involved in the rapid hydrolysis of acetylcholine. Through inhibition of acetylcholinesterase, ChEIs, such as donepezil, rivastigmine, and galantamine, allow acetylcholine to accumulate. The rationale for prescribing ChEIs for treating symptoms of ADRD is to increase acetylcholine levels, which increases neuronal activity. However, this is a strategy that has low effectiveness \[[@bib4]\], and there is no evidence that ChEIs prevent the underlying dementing process \[[@bib5]\].

ChEIs have additional pharmacological actions. Rivastigmine inhibits butyrylcholinesterase with a similar affinity to acetylcholinesterase. The therapeutic effect and resulting clinical consequences of this is unknown \[[@bib6],[@bib7]\]. Galantamine potentiates the action of acetylcholine on nicotinic receptors, which may influence neuronal processes, such as synaptic efficacy and neuroprotection \[[@bib8],[@bib9]\]. Evidence suggests the cholinergic adverse effects of these drugs may cause gastrointestinal, neurological, cardiovascular, and urinary disorders \[[@bib10],[@bib11]\]. In severe instances, these drugs may increase vagal tone and, thereby, precipitate bradycardia \[[@bib12]\]. Multiple U.S. Food and Drug Administration safety alerts have raised concerns of increased mortality and serious cardiovascular adverse events in patients taking ChEIs for mild cognitive impairment versus placebo-treated patients \[[@bib13]\].

A Cochrane database systematic review (Russ \[[@bib14]\]) found no significant difference in progression to dementia between ChEIs and placebo at 12 months. They found ChEIs increased overall adverse events compared with placebo but found no significant differences between the groups for serious adverse events, cardiac problems, depression, or death. Earlier systematic reviews found small improvements or unchanged cognitive benefits with ChEIs versus placebo \[[@bib15]\]. In addition, some trials within the systematic reviews showed an unexplained increased death rate.

Effective October 22, 2007, the British Columbia Ministry of Health began providing financial coverage of the ChEIs through the Alzheimer\'s Drug Therapy Initiative to address clinical knowledge gaps around the safety and effectiveness of these drugs \[[@bib16]\]. Patients receiving a baseline assessment score on the Standardized Mini--Mental State Examination of mild to moderate cognitive impairment are eligible for full financial coverage of a ChEI.

We investigated the risk of mortality between the ChEIs for new users during the Alzheimer\'s Drug Therapy Initiative. Serious cardiovascular events were investigated as a secondary outcome. We also looked at time to entry into a residential care facility. Supporting people with ADRD to function in their own homes for as long as possible is a stated priority of the B.C. Provincial Guide to Dementia Care \[[@bib17]\].

2. Methods {#sec2}
==========

2.1. Data {#sec2.1}
---------

We obtained access to the B.C. Ministry of Health administrative health claims database through a secure access environment. The database contains linkable, but deidentified, health service records containing all prescriptions dispensed at community pharmacies, physician services, hospital separations, and vital statistics data in British Columbia. We assume that the completeness and accuracy of the data is comparable to other administrative databases \[[@bib18],[@bib19]\].

2.2. Study design and source population {#sec2.2}
---------------------------------------

We conducted a retrospective, propensity score--adjusted cohort study. The source population for the study was all B.C. residents between October 2007 and March 2016 who were registered in the provincial universal medical services plan. Federally insured patients, such as indigenous people, federal police officers, and members of the armed forces and their families, were excluded from the source population because they are not included in the data set. Excluded patients composed about 7% of the provincial population. The source population numbered 4.42 million in 2016 \[[@bib20]\].

2.3. Study cohorts {#sec2.3}
------------------

New users of ChEIs were identified during the study period as having no ChEI prescription in the previous 365 days. New users were categorized into 5 exposure groups based on their first prescription: (1) low-dose donepezil (≤7.5 mg/day), (2) high-dose donepezil (\>7.5 mg/day), (3) galantamine, (4) rivastigmine patch, and (5) rivastigmine oral. Low-dose donepezil was defined based on receiving a dose equivalent to, or below, the World Health Organization\'s Defined Daily Dose. Low-dose donepezil, the most frequently prescribed ChEI, was assigned as the reference drug, providing four comparison cohorts instead of a single multinomial regression approach.

The date of each patient\'s first ChEI dispensing was defined as the index date. Patients were excluded from the study cohorts if they were under 50 years old on the index date, in a residential care facility in the 2-year period before index date, did not have continuous medical insurance in the 1-year period before index date, or dispensed more than one ChEI on index date.

2.4. Study outcomes {#sec2.4}
-------------------

Our primary outcome was all-cause mortality. Secondary outcomes were (1) composite cardiovascular serious adverse events and (2) entry into a residential care facility. Composite cardiovascular events consisted of a hospital admission for myocardial infarction (ICD-9: 410), coronary artery disease (ICD-9: 411-414), heart failure (ICD-9: 428), arrhythmia (including atrial fibrillation) (ICD-9: 427), and peripheral arterial or vascular disease (ICD-9: 443.9, 440). Entry into a residential care facility was determined by the presence of a government-subsidized prescription under the residential care benefit plan.

2.5. Data analysis {#sec2.5}
------------------

Safety of ChEIs was compared using time-to-event Cox proportional regression. Four drug comparisons were made: (1) low-dose donepezil versus high-dose donepezil, (2) low-dose donepezil versus galantamine, (3) low-dose donepezil versus rivastigmine patch, and (4) low-dose donepezil versus oral rivastigmine. Patient follow-up was censored at the earliest occurrence of our study outcome, death, end of the study period (31 March 2016), emigration from BC, therapy discontinuation, or crossover to another study cohort. Sensitivity analyses used log-binomial regression to estimate relative risk at 6-month and 12-month fixed follow-up periods \[[@bib21]\]. All outcome models were adjusted for history of prior cardiovascular events, smoking, and high-dimensional propensity scores meant to capture other confounding factors. The high-dimensional propensity score methods have been previously described in detail here \[[@bib22]\].

2.6. Confounders {#sec2.6}
----------------

Potential confounders were measured before exposure to a ChEI using hospital and physician diagnostic codes, dispensed prescription records, and patient demographic records. The following covariates were included in the outcome model if they occurred within two years before index date: arrhythmia (ICD-9: 427; ICD-10: I49), myocardial infarction (ICD-9: 410; ICD-10: I21), stroke (ICD-9: 430-434, 436; ICD-10: I60, I61, I64, I63), angina (ICD-9: 413; ICD-10: I20), congestive heart failure (ICD-9: 428; ICD-10: I50), cerebrovascular disease (ICD-10: I60-I69), coronary artery disease (ICD-9: 411, 412, 414; ICD-10: I22-I25, Z95.1, Z95.5, Z98.61), peripheral arterial disease (ICD-9: 440, 443.9; ICD-10: I70, I73.9), or diabetes (ICD-9: 250; ICD-10: E10-E14). Other covariates included sex, age group (50--64, 65--74, 75--84 as reference, 85+), and smoking status (current or past smoker).

The following predefined demographic and diagnostic covariates were incorporated into the high-dimensional propensity score model: age group, sex, family income, index year, time since ADRD diagnosis, more than five distinct medications dispensed in previous year (yes/no), more than five physician visits in previous year (yes/no).

3. Results {#sec3}
==========

There were 34,338 patients from the source population who initiated a ChEI between 22 October 2007 and 31 March 2016. Of those, 29,047 patients remained eligible for the study after exclusions for not meeting medical insurance eligibility criteria (5.4%), resident of a long-term care facility in prior two years (7.9%), initiating more than one ChEI on cohort entry date (1.8%), and age under 50 years (0.4%).

Baseline patient characteristics of the study cohorts ([Table 1](#tbl1){ref-type="table"}) were similar for average age of patients (80.5 years). The proportion of female patients was lowest in the oral rivastigmine (48%) cohort and highest in the low-dose donepezil (60%) cohort. Smokers, past or current, ascertained by the presence of a diagnosis of chronic obstructive pulmonary disease or use of a prescription smoking cessation therapy were similar among all cohorts. Galantamine users had the highest proportion of cardiovascular-related hospital admissions in the 2-year period before index date, including stroke, unstable angina, cerebrovascular disease, coronary artery disease, and peripheral arterial disease. Prior medication history was similar, other than prior use of antipsychotics, which was nearly double (19.5%) with oral rivastigmine compared with the low-dose donepezil cohort (10.0%).Table 1Baseline patient characteristicsCharacteristicsDonepezil (low dose)Donepezil (high dose)GalantamineRivastigmine (patch)Rivastigmine (oral)N or mean (n = 15,586)% or SDN or mean (n = 2519)% or SDN or mean (n = 5926)% or SDN or mean (n = 4286)% or SDN or mean (n = 730)% or SDAge (years), mean (IQR)80.7 (76-86)78.7 (74-85)80.8 (77-86)80.3 (76-85)79.2 (75-84)Female, n (%)93666013055234005723195434748Low family income[∗](#tbl1fnlowast){ref-type="table-fn"} (\<\$30k), n (%)3469225072013892311692713919Year of study cohort entry, n (%) 2007 (Oct 22--Dec 31)32329742294-0649 20081763114371712772294218625 2009176711371151277225581312016 201019661337515105118744177610 20112241143601478713791187510 201223501535514554977418598 201323361525610348665715689 20142182142159315553613628 2015 (up to March 31)65845328811323203Duration of ADRD (years), mean (SD)1.042.31.022.31.072.41.102.31.092.2High-dose first prescription[†](#tbl1fndagger){ref-type="table-fn"}, n (%)\-\-\--1131.9230.5101.4High-dose second prescription[†](#tbl1fndagger){ref-type="table-fn"}, n (%)347122\--1342.3110.3111.5Follow-up time (years)[‡](#tbl1fnddagger){ref-type="table-fn"}, mean (SD)3.41 (1.95)3.86 (2.05)4.14 (2.12)3.28 (1.76)3.95 (2.26)Smoker[§](#tbl1fnSection){ref-type="table-fn"} (past or current), n (%)69554510754326604519674631143Number of hospital admissions in previous year 0, n (%)10,7096917777140806927686548266 1--2, n (%)17781128811729125231210815 3+, n (%)309920454181117199952314019Number of physician visits in previous year, mean (SD)21 (18.2)20.9 (16.7)21 (17.2)25.2 (21.6)24.1 (19.8)Prior medical history[¶](#tbl1fnpara){ref-type="table-fn"} (2 years), n (%) Atrial fibrillation or flutter239315.433613.398216.670416.410514.4 COPD, n (%)220014.133013.187114.763414.89012.3 Diabetes mellitus383424.662124.7146724.8116027.118325.1 Myocardial infarction2181.4291.2711.2621.491.2 Hypertension954561.2142056.4370162.5257360.044160.4Prior hospital admission (2 years), n (%) Stroke2091.3341.31252.1821.9101.4 Unstable angina1130.7190.8540.9300.750.7 Congestive heart failure4092.6481.91592.71242.9172.3 Cerebrovascular disease3031.9552.21652.81122.6192.6 Coronary artery disease5703.7913.62614.41724.0314.2 Peripheral arterial disease700.460.2320.5110.320.3Prior medication history (1 year), n (%) Other anticholinergics, n (%)249116.037414.895216.173217.115020.5 Lipid-lowering agents, n (%)630740.599539.5254643.0180442.129840.8 ACE inhibitors, n (%)514633.071828.5214636.2137532.126836.7 ARBs, n (%)240915.536514.591715.570216.410214.0 Beta-blockers, n (%)394425.355322.0156326.4110225.719526.7 Antidepressants, n (%)489831.471128.2177630.0148234.625534.9 Antipsychotics, n (%)156510.02359.35699.659213.814219.5 Anxiolytics/sedatives/hypnotics, n (%)371723.860524.0136022.9118127.620828.5[^1][^2][^3][^4][^5][^6]

Compared with low-dose donepezil, galantamine was associated with a 16% lower 3-year risk of mortality (adjusted hazard ratio \[aHR\]: 0.84, 95% confidence interval \[CI\]: 0.60--1.18). High-dose donepezil had similar risk (aHR: 0.97, 95% CI: 0.61--1.54), and the rivastigmine patch had 29% higher risk (aHR: 1.29, 95% CI: 0.93--1.79) ([Table 2](#tbl2){ref-type="table"}). The mortality differences were not statistically significant (*P* \< .05).Table 2Cox proportional hazards for mortality, serious cardiovascular events, and entry into a residential care facilityN3 yearCumulative mortality eventsCrude rate per 100 PYsPropensity score--adjusted hazard ratioAll-cause mortality, time-to-event, Cox proportional hazards Low-dose donepezil (reference)15,5861475.80 High-dose donepezil2519235.350.97 (0.61--1.54) Galantamine5926515.290.84 (0.60--1.18) Rivastigmine---patch42868610.821.29 (0.93--1.79) Rivastigmine---oral730\<50.49 (0.17--1.36)Serious cardiovascular events, time-to-event, Cox proportional hazards Low-dose donepezil (reference)15,5863315.84 High-dose donepezil2519505.391.02 (0.75--1.39) Galantamine59261065.320.78 (0.62--0.98) Rivastigmine---patch428612810.910.98 (0.77--1.25) Rivastigmine---oral730163.530.87 (0.51--1.48)Entry into residential care, time-to-event, Cox proportional hazards Low-dose donepezil (reference)15,5864475.86 High-dose donepezil2519665.410.97 (0.74--1.28) Galantamine59261355.340.72 (0.59--0.89) Rivastigmine---patch428618210.971.16 (0.95--1.42) Rivastigmine---oral730222.550.88 (0.56--1.37)

Compared with low-dose donepezil, galantamine was associated with a lower risk of serious cardiovascular events (aHR: 0.78, 95% CI: 0.62--0.98) and entry into a residential care facility (aHR: 0.72, 95% CI: 0.59--0.89) ([Table 2](#tbl2){ref-type="table"}). Comparison with the oral rivastigmine could not be completed due to small-cell data restrictions.

In the 12-month fixed follow-up sensitivity analysis of cardiovascular events, galantamine was associated with an 18% lower risk (adjusted risk ratio \[RR\]: 0.82 (0.72--0.93) and rivastigmine patch was associated with a 15% higher risk (RR: 1.15 \[1.01--1.32\]), compared with low-dose donepezil. In the 6-month fixed follow-up analysis of cardiovascular events, there was no significant difference between low-dose donepezil and any of the study medications.

Compared with low-dose donepezil, galantamine was associated with a lower risk of mortality at 6 months (RR: 0.83, 95% CI: 0.69--1.01) and 12 months (RR: 0.82, 95% CI: 0.72--0.93), although the 6-month result was nonsignificant. The rivastigmine patch was associated with an increased risk of mortality at 6 months (RR: 1.21, 95% CI: 0.99--1.49) and at 12 months (RR: 1.15, 95% CI: 1.01--1.32), although the 6-month result was nonsignificant. Both formulations of rivastigmine, patch and oral, were also associated with a 12-month increased risk of entry into residential care (RR: 1.14, 95% CI: 1.03--1.26) and (RR: 1.275, 95% CI: 1.06--1.52), respectively ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}).Table 3Six-month fixed follow-up log-binomial regressionNNumber of outcomesCrude risk ratio (95% confidence interval)Age-sex adjustedFully adjustedRisk ratio (95% confidence interval)*P*-valueRisk ratio (95% confidence interval)*P*-valueCrude and adjusted odds ratio, all-cause mortality, 6-month fixed follow-up Low-dose donepezil (reference)15,586440 High-dose donepezil2519530.75 (0.56--0.99)0.81 (0.61--1.08)0.1470.83 (0.62--1.11)0.209 Galantamine59261500.90 (0.75--1.08)0.89 (0.74--1.06)0.1940.83 (0.69--1.01)0.066 Rivastigmine---patch42861581.31 (1.09--1.56)**1.31 (1.09**--**1.56)0.003**1.21 (0.99--1.47)0.062 Rivastigmine---oral730170.82 (0.51--1.33)0.88 (0.54--1.41)0.5850.74 (0.45--1.22)0.243Crude and adjusted odds ratios, cardiovascular events, 6-month fixed follow-up Low-dose donepezil (reference)15,586517 High-dose donepezil2519790.95 (0.75--1.19)1.00 (0.80--1.27)0.6371.09 (0.85--1.38)0.500 Galantamine59261610.82 (0.69--0.98)**0.81 (0.68**--**0.96)0.0170.79 (0.66**--**0.96)0.015** Rivastigmine---patch42861400.98 (0.82--1.18)0.99 (0.82--1.19)0.8910.94 (0.77--1.15)0.543 Rivastigmine---oral730271.12 (0.76--1.63)1.16 (0.79--1.69)0.4470.90 (0.61--1.34)0.606Crude and adjusted odds ratios, entry to residential care, 6-month fixed follow-up Low-dose donepezil (reference)15,586920 High-dose donepezil25191080.73 (0.60--0.88)**0.81 (0.67**--**0.99)0.037**0.82 (0.67--1.01)0.058 Galantamine59262980.85 (0.75--0.97)**0.86 (0.76**--**0.97)0.0170.80 (0.70**--**0.92)0.001** Rivastigmine---patch42863011.19 (1.05--1.35)**1.22 (1.08**--**1.39)0.0021.19 (1.03**--**1.36)0.015** Rivastigmine---oral730631.46 (1.15--1.87)**1.62 (1.27**--**2.06)0.0001**1.26 (0.98--1.63)0.077[^7]Table 4Twelve-month fixed follow-up log-binomial regressionNNumber of outcomesCrude risk ratio (95% confidence interval)Age- and sex-adjustedProp. Score adjustedRisk ratio (95% confidence interval)*P*-valueRisk ratio (95% confidence interval)*P*-valueCrude and adjusted odds ratio, all-cause mortality, 12-month fixed follow-up Low-dose donepezil (reference)15,586990 High-dose donepezil25191340.84 (0.70--0.99)0.90 (0.76--1.07)0.2440.93 (0.77--1.11)0.408 Galantamine59263350.89 (0.79--1.00)**0.88 (0.78**--**0.99)0.0320.82 (0.72**--**0.93)0.002** Rivastigmine---patch42863291.21 (1.07--1.36)**1.21 (1.07**--**1.36)0.0021.15 (1.01**--**1.32)0.031** Rivastigmine---oral730481.04 (0.78--1.37)1.08 (0.82--1.43)0.5890.97 (0.72--1.29)0.815Crude and adjusted odds ratios, cardiovascular events, 12-month fixed follow-up Low-dose donepezil (reference)15,586914 High-dose donepezil25191250.85 (0.71--1.02)0.90 (0.75--1.08)0.2640.96 (0.80--1.16)0.708 Galantamine59263000.86 (0.76--0.98)**0.86 (0.75**--**0.97)0.0160.83 (0.73**--**0.95)0.007** Rivastigmine---patch42862400.95 (0.83--1.10)0.96 (0.84--1.10)0.5600.94 (0.81--1.09)0.434 Rivastigmine---oral730400.93 (0.69--1.27)0.98 (0.72--1.33)0.8980.85 (0.61--1.16)0.305Crude and adjusted odds ratios, entry to residential care, 12-month fixed follow-up Low-dose donepezil (reference)15,5861702 High-dose donepezil25192180.79 (0.69--0.91)0.88 (0.77--1.00)0.0510.90 (0.78--1.03)0.117 Galantamine59266591.02 (0.94--1.11)1.02 (0.94--1.11)0.5660.95 (0.87--1.04)0.284 Rivastigmine---patch42865291.13 (1.03--1.24)**1.16 (1.06**--**1.27)0.0011.14 (1.03**--**1.26)0.011** Rivastigmine---oral7301131.42 (1.19--1.69)**1.54 (1.30**--**1.83)\<.00011.27 (1.06**--**1.52)0.011**[^8]

4. Interpretation {#sec4}
=================

This study compares ChEIs in terms of mortality, serious cardiovascular events, and entry into a residential care facility. Donepezil users were divided into low- and high-dose exposure groups based on WHO Defined Daily Dose. Nearly all users of galantamine and rivastigmine (98%) used the single WHO Defined Daily Dose.

The 3-year risk of serious cardiovascular events was 22% lower (aHR 0.78 CI: 0.62--0.98) and all-cause mortality was 16% lower (aHR 0.84 CI: 0.60--1.18) in galantamine versus low-dose donepezil, although the mortality results were not significant at the conventional α level of 0.05. Similar results were seen in both fixed follow-up sensitivity analyses. A Danish cross-national study comparing cardiovascular safety of dementia medications found similar benefits for galantamine (29% lower risk of heart failure \[aHR 0.71 CI: 0.46--1.10\]) \[[@bib23]\].

Prior hospital admission for several cardiovascular conditions was highest among galantamine users. Although this usually suggests patients were at a higher risk of future cardiovascular events, an alternative explanation could be that these patients were more closely monitored and more aggressively treated for vascular risk factors, resulting in lower cardiovascular events.

Entry into residential care was studied as a co-secondary outcome as a measure of net benefit over harm. Our results show a 28% lower 3-year risk of entry into a residential care facility with galantamine versus low-dose donepezil (aHR: 0.72 CI: 0.62--0.98). These findings are also consistent with a net benefit of treatment over harm for galantamine and may also be related to a previous finding of longer persistence and better adherence for patients on galantamine versus donepezil \[[@bib24]\].

Residual confounding is a possible limitation of our results because of the nonrandomized study design. Baseline characteristics of the study cohorts indicate comparable age, smoking status, and prior medical history. Low-dose donepezil had the highest proportion of females (60%). This was likely due to weight-based dosing. Rivastigmine users had the highest prior use of antipsychotics. There is a positive correlation between cognitive decline, progression of neurodegeneration, and psychosis in patients with ADRD \[[@bib25]\]. Previous research has shown that rivastigmine users have a lower rate of antipsychotic prescriptions compared with donepezil patients in a base cohort of antipsychotic naïve patients \[[@bib26]\]. These findings may influence physicians to preferentially prescribe rivastigmine over other ChEIs to patients with symptoms of psychosis. In addition, the Alzheimer\'s Drug Therapy Initiative required regular cognitive assessments; our study findings may not be generalizable to jurisdictions with alternative health care systems.

A significant strength of our study was the use of the B.C. Ministry of Health administrative claims database, which captures all prescriptions dispensed at a community pharmacy regardless of payer. Dispensed prescriptions are linkable to physician services, hospital discharge abstracts, and client demographic information via an encrypted patient identifier. The comprehensiveness of the databases for the B.C. population reduces the risk of exposure misclassification, which is known to substantially affect risk estimates in observational studies \[[@bib27]\] and allows for generalizing results to a wide population.

Our study found that galantamine has a superior safety profile compared with low-dose donepezil and was associated with a lower risk of entry into a residential care facility. The rivastigmine patch was associated with a higher risk of mortality and a higher risk of entry into a residential care facility. High-dose donepezil had a similar safety and effectiveness profile compared with low-dose donepezil. Given the absence of randomized trial data showing clinically meaningful benefit of ChEI therapy in ADRD, our study suggests that preferential use of galantamine may at least be associated with fewer adverse events than treatment with donepezil or rivastigmine and may also be associated with longer independent living before requiring a residential care facility.Research in context1.A clinically meaningful improvement in cognitive function has not been established between cholinesterase inhibitors (ChEIs) and placebo in clinical trials of patients with Alzheimer\'s disease and related dementia, yet ChEIs are commonly prescribed.2.Using population-based data during a government-sponsored reimbursement program, we examined the comparative safety of ChEIs. Compared with the most common treatment, low-dose donepezil, we found galantamine was associated with a lower risk of cardiovascular events and mortality. Galantamine use was also associated with longer independent living, delaying the need for a residential care facility.3.Given the absence of randomized trial data showing clinically meaningful benefit of ChEI therapy, preferential use of galantamine may at least be associated with a superior safety profile compared with donepezil or rivastigmine.

Supplementary Data {#appsec1}
==================

Supplementary Fig. 1Flow chart of patients included in the study cohorts.Supplementary Fig. 2Propensity score distribution and model statistics.
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[^1]: Abbreviations: IQR, interquartile range; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers.

[^2]: Net family income in Canadian dollars from the most recent income tax return (1 Canadian dollar ≈ .75 US dollar).

[^3]: High-dose defined as a dispensed daily dose on the first ChEI prescription that is higher than the WHO Defined Daily Dose (DDD).

[^4]: Follow-up time shown for primary outcome (mortality).

[^5]: Smoking status based on history of diagnosed COPD or use of a smoking cessation medication (varenicline, Zyban, or nicotine replacement products).

[^6]: Hospital separation record or physician visit diagnosis within 2 years before the index date.

[^7]: Bold values indicate a confidence interval that does not include 1.

[^8]: Bold values indicate a confidence interval that does not include 1.
